Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Azad N, et al. Among authors: kohn ec. Mol Cell Proteomics. 2013 Jun;12(6):1621-31. doi: 10.1074/mcp.M112.026427. Epub 2013 Feb 28. Mol Cell Proteomics. 2013. PMID: 23449826 Free PMC article. Clinical Trial.
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. Among authors: kohn ec. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC. Annunziata CM, et al. Among authors: kohn ec. Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068097 Free PMC article. Clinical Trial.
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC. Lee JM, et al. Among authors: kohn ec. J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun. J Natl Cancer Inst. 2014. PMID: 24842883 Free PMC article. Clinical Trial.
285 results